European regulators approved Pfizer’s Talzenna (talazoparib) as a treatment for inherited breast cancer.
Talzenna targets adults with advanced-stage breast cancer with the inherited gene mutation BRCA. The FDA approved the daily pill last October.
The European Commission’s approval comes after Pfizer handed up data from the EMBRACA trial, a Phase III study that showed patients in the Talzenna group saw their disease progression slow by 46 percent compared to chemotherapy. Talzenna also doubled the overall response rate compared to patients in the chemo group, Pfizer said.